Skip Ribbon Commands
Skip to main content
Sign In
{{'GLOBAL_MESSAGE_HEADLINE' | translate}}
{{'GLOBAL_MESSAGE_CHOOSE_LANG' | translate}}
en
日本語
中文
{{'GLOBAL_MESSAGE_OR' | translate}}
{{'GLOBAL_MESSAGE_SET_COUNTRY' | translate}}
{{'ELOQUA_BANNER_DECLINE_CONFIRM' | translate}}
{{'ELOQUA_BANNER_DECLINE_CONFIRM_CLOSE' | translate}}
{{'ELOQUA_BANNER_ACCEPT' | translate}}
{{'ELOQUA_BANNER_DECLINE' | translate}}
Autologous Biologics
Overview BMAC PRP Adipose Tissue SmartPrep Ordering Info

AUTOLOGOUS BIOLOGICS:


Harnessing the Power of a Patient’s Own Cells

Autologous biologics products are created by collecting and concentrating naturally occurring cells from a patient’s own body; these products offer physicians alternative options for patients.

In the procedure, cells are drawn from the patient, separated and concentrated using a specialized procedure pack and centrifuge, and then delivered to the patient’s application site. Processing can take less than 15 minutes. Because the biologic is prepared from the patient’s own cells, there is a significantly reduced risk of rejection or immune response using autologous biologics as compared to alternative treatment options.1,2

Which biologic is right for your patients?


Concentrated Bone Marrow Aspirate

LEARN MORE ABOUT BMAC®
Platelet-Rich Plasma (PRP)

LEARN MORE ABOUT PRP
Concentrated Adipose Tissue

LEARN MORE ABOUT ADIPOSE TISSUE

Terumo BCT Autologous Biologics



Terumo BCT is a global leader in blood component, therapeutic apheresis, cellular and autologous biologic technologies. We believe in the potential of cells to do even more for patients than they do today. This belief inspires us to share our expertise in cell separation and collaborate with customers to advance the practice of autologous biologic technologies together.

We welcome the opportunity to help you navigate autologous biologics and find the products that best fit your needs as a clinician.







1Lohan P, Treacy O, Griffin M, Ritter T, Ryan A. Anti-donor immune responses elicited by allogeneic mesenchymal stem cells and their extracellular vesicles: are we still learning? Front Immunol. 2017;8:1626.

2Sivanathan K, Gronthos S, Rojas-Canales D, Thierry B, Coates P. Interferon-gamma modification of mesenchymal stem cells: implications of autologous and allogeneic mesenchymal stem cell therapy in allotransplantation. Stem Cell Reviews and Reports. 2014;10(3):351-375.


Risk Information: These procedures require needle access, possibly resulting in discomfort, tenderness, bruising, swelling, bleeding or pain at the access site, at which there is a small risk of infection. Lightheadedness, fainting, nausea or vomiting may occur. Before any medical procedure, review prescription and nonprescription medications and any natural or herbal remedies your patient is taking or plans to take.

​​​​​​

{{'SEARCH_MODAL_TITLE' | translate }}
{{'SEARCH_MODAL_OR' | translate }}

{{'SEARCH_MODAL_BROWSE' | translate }}
{{'SEARCH_MODAL_CHOOSE_LANGUAGE' | translate }} {{'SEARCH_MODAL_CHANGE_LANGUAGE' | translate }}
{{$index+1}}. {{s.label}}